We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as colorectal, liver, and lung cancer. By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in blood-based cancer detection.
Year founded1998
Served areaWorldwide
Headcount32
HeadquartersGeneststraße 5, 10829 Berlin – Germany
Report | Q1 | H1 | Q3 | FY |
---|---|---|---|---|
Consolidated Report | ENG GER | GER ENG | GER ENG | ENG |
Corporate Governance Report | ||||
Company Presentation | ||||
General Presentation | ||||
Sustainability Report | ||||
Remuneration Report |
Report | Q1 | H1 | Q3 | FY |
---|---|---|---|---|
Consolidated Report | ENG | |||
Corporate Governance Report | ||||
Company Presentation | ||||
General Presentation | ||||
Sustainability Report | ||||
Remuneration Report |
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
27.12.22 | Ho, Dr. Selwyn | Board | Buy | 4,200.00 € |
23.12.22 | von Prondzynski, Heino | Supervisory board | Buy | 5,625.00 € |
22.12.22 | Lubenow, Dr. Helge | Supervisory board | Buy | 1,934.20 € |
22.12.22 | Ahlers, Felix | Board | Other | 22,000.00 € |
20.12.22 | von Prondzynski, Heino | Supervisory board | Buy | 3,680.00 € |
16.12.22 | Lindenice GmbH | Board | Buy | 7,400.00 € |
16.12.22 | IDAB Management GmbH | Supervisory board | Buy | 7,400.00 € |
16.12.22 | Ho, Dr. Selwyn | Board | Buy | 6,780.00 € |
14.12.22 | von Prondzynski, Heino | Supervisory board | Buy | 40,000.00 € |
16,357,301
IPOJuly 19, 2004
Designated Sponsor(s)Pareto Securities
Stock exchange(s)Frankfurt Stock Exchange